Clinuvel Pharmaceuticals Financial Overview
Clinuvel Pharmaceuticals 's market cap is currently $418.79M. The company's EPS TTM is $0.292938115; its P/E ratio is 16.46; and it has a dividend yield of 0.42%. Clinuvel Pharmaceuticals is scheduled to report earnings on August 27, 2025, and the estimated EPS forecast is $0.18. See an overview of income statement, balance sheet, and cash flow financials.
